-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Benzinga·08/12/2026 16:05:50
Listen to the news
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.